Accessibility Menu
Oncolytics Biotech Stock Quote

Oncolytics Biotech (NASDAQ: ONCY)

$1.17
(-0.8%)
-0.01
Price as of October 23, 2025, 3:56 p.m. ET

KEY DATA POINTS

Current Price
$1.18
Daily Change
(-0.8%) $0.01
Day's Range
$1.16 - $1.21
Previous Close
$1.18
Open
$1.18
Beta
0.87
Volume
751,802
Average Volume
1,023,579
Market Cap
118.4M
Market Cap / Employee
$1.18M
52wk Range
$0.33 - $1.51
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$0.27
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Oncolytics Biotech Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ONCY-3.28%-47.79%-12.18%-98%
S&P+14.5%+93.32%+14.09%+525%

Oncolytics Biotech Company Info

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.07M5.2%
Market Cap$68.66M-8.6%
Market Cap / Employee$2.45M0.0%
Employees283.7%
Net Income-$4.45M16.0%
EBITDA-$4.06M29.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$7.75M-52.5%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.44M-32.8%
Short Term Debt$0.21M29.7%

Ratios

Q2 2025YOY Change
Return On Assets-114.75%-27.7%
Return On Invested Capital-168.91%10961.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$4.12M17.9%
Operating Free Cash Flow-$4.12M16.0%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book5.0010.5110.5814.81236.57%
Price to Tangible Book Value5.0010.5110.5814.81236.57%
Enterprise Value to EBITDA-7.43-10.18-7.61-14.8646.54%
Return on Equity-144.2%-184.7%-211.2%-244.8%78.41%
Total Debt$0.79M$0.74M$0.69M$0.65M-20.21%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.